Absence of a classically activated macrophage cytokine signature in Peripheral spondylarthritis, including psoriatic arthritis

Arthritis and Rheumatism

Volumn 60, Issue 4, 2009, Pages 966-975

  Vandooren, Bernard ^a,b   Noordenbos, Troy ^a   Ambarus, Carmen ^a   Krausz, Sarah ^a   Cantaert, Tineke ^a   Yeremenko, Nataliya ^a   Boumans, Maartje ^a   Lutter, Rene ^a   Tak, Paul P ^a   Baeten, Dominique ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; CD200 RECEPTOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; SYNOVIAL FLUID;

ADULT; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; BIOPSY; CYTOKINES; FEMALE; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; SPONDYLARTHRITIS; SYNOVIAL MEMBRANE;

EID: 65249143893     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24406     Document Type: Article

References (54)

1. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.
2. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64.
3. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-6.
4. Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and anti-inflammatory stimuli. J Leukoc Biol 2000;67:97-103.
5. Sulahian TH, Hogger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, et al. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000;12:1312-21.
6. Baeten D, Demetter P, Cuvelier CA, Kruithof E, Van Damme N, De Vos M, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002;196:343-50.
7. Baeten D, Moller HJ, Delanghe J, Veys EM, Moestrup SK, De Keyser F. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum 2004;50:1611-23.
8. Baeten D, Kruithof E, De Rycke L, Vandooren B, Wyns B, Boullart L, et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum 2004;50: 2931-41.
9. Baeten D, Kruithof E, De Rycke L, Boots AM, Mielants H, Veys EM, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005;7:359-69.
10. De Rycke L, Baeten D, Foell D, Kruithof E, Veys EM, Roth J, et al. Differential expression and response to anti-TNFa treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005;206:17-27.
11. Kruithof E, De Rycke L, Vandooren B, De Keyser F, FitzGerald O, McInnes I, et al, on behalf of the OMERACT Special Interest Group on Synovial Analysis in Clinical Trials. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006;54:1795-804.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
14. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, and the CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
15. Baeten D, Van den Bosch F, Elewaut D, Stuer A, Veys EM, De Keyser F. Needle arthroscopy of the knee with synovial biopsy sampling: technical experience in 150 patients. Clin Rheumatol 1999;18:434-41.
16. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003;171:3034-46.
17. Jenmalm MC, Cherwinski H, Bowman EP, Philips JH, Sedgwick JD. Regulation of myeloid cell function through the CD200 receptor. J Immunol 2006;176:191-9.
18. Erwig LP, Kluth DC, Walsh GM, Rees AJ. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J Immunol 1998;161:1983-8.
19. Matsumoto T, Tsurumoto T, Shindo H. Interleukin-6 levels in synovial fluids of patients with rheumatoid arthritis correlated with the infiltration of inflammatory cells in synovial membrane. Rheumatol Int 2006;26:1096-100.
20. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-γ- and CD40L- mediated costimulation. J Leukoc Biol 2006;79:285-93.
21. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006;177:7303-11.
22. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-61.
23. Sims AM, Timms AE, Bruges-Armas J, Burgos-Vargas R, Chou CT, Doan T, et al, on behalf of the International Genetics of Ankylosing Spondylitis. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis 2008;67:1305-9.
24. Rahman P, Sun S, Peddle L, Snelgrove T, Melay W, Greenwood C, et al. Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 2006;54:2321-5.
25. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14, 500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
26. Keller C, Webb A, Davis J. Cytokines in the seronegative spondyloarthropathies and their modification by TNF blockade: a brief report and literature review. Ann Rheum Dis 2003;62:1128-32.
27. Canete JD, Martinez SE, Farres J, Sanmarti R, Blay M, Gomez A, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon 7 is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis 2000;59:263-8.
28. Rudwaleit M, Siegert S, Yin Z, Eick J, Thiel A, Radbruch A, et al. Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis 2001;60:36-42.
29. Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα. Ann Rheum Dis 2001;60:750-5.
30. Van Damme N, De Vos M, Baeten D, Demetter P, Mielants H, Verbruggen G, et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. Ann Rheum Dis 2001;60:495-9.
31. Gratacos J, Collado A, Filella X, Sanmarti R, Canete J, Llena J, et al. Serum cytokines (IL-6, TNF-α, IL-1β and IFN-γ) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
32. Sonel B, Tutkak H, Duzgun N. Serum levels of IL-1β, TNF-α, IL-8, and acute phase proteins in seronegative spondyloarthropathies. Joint Bone Spine 2002;69:463-7.
33. Toussirot E, Lafforgue P, Boucraut J, Despieds P, Schiano A, Bernard D, et al. Serum levels of interleukin 1-β, tumor necrosis factor-α, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies. Rheumatol Int 1994;13:175-80.
34. Bas S, Kvien TK, Buchs N, Fulpius T, Gabay C. Lower level of synovial fluid interferon-γ in HLA-B27-positive than in HLA-B27- negative patients with Chlamydia trachomatis reactive arthritis. Rheumatology (Oxford) 2003;42:461-7.
35. Smith JA, Barnes MD, Hong D, DeLay ML, Inman RD, Colbert RA. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-γ dysregulation. Arthritis Rheum 2008;58:1640-9.
36. Ji JD, Tassiulas I, Park-Min KH, Aydin A, Mecklembrauker I, Tarakhosky A, et al. Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med 2003;197:1573-83.
37. Antoniv TT, Ivashkiv LB. Dysregulation of interleukin- 10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum 2006;54:2711-21.
38. Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, et al. Involvement of matrix met al.loproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor α blockade in spondylarthropathy. Arthritis Rheum 2004; 50:2942-53.
39. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
40. Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005;64:529-36.
41. Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005;52:3898-909.
42. Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005;7:439-44.
43. De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D. Tumor necrosis factor α blockade treatment downmodulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005;52:2146-58.
44. Rihl M, Kruithof E, Barthel C, De Keyser F, Veys EM, Zeidler H, et al. Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. Ann Rheum Dis 2005;64:1542-9.
45. Rihl M, Kellner H, Kellner W, Barthel C, Yu DT, Tak PP, et al. Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. Arthritis Rheum 2008;58:3430-5.
46. Vandooren B, Cantaert T, ter Borg M, Noordenbos T, Kuhlman R, et al. Tumor necrosis factor α drives cadherin 11 expression in rheumatoid inflammation. Arthritis Rheum 2008;58:3051-62.
47. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-a induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-8.
48. Zwerina J, Redlich K, Polzer K, Joosten L, Kronke G, Distler J, et al. TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A 2007;104:11742-7.
49. Smeets RL, Veenbergen S, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB, et al. A novel role for suppressor of cytokine signaling 3 in cartilage destruction via induction of chondrocyte desensitization toward insulin-like growth factor. Arthritis Rheum 2006;54:1518-28.
50. Vandooren B, Cantaert T, van Lierop MJ, Bos E, De Rycke L, Veys EM, et al. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis. Ann Rheum Dis 2008. E-pub ahead of print.
51. Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008;58:718-29.
52. Diarra D, Stolina M, Polzer K, Zwerina J, Omisnky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
53. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31.
54. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligoand polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7:569-80.